TWI747816B - 眼用組合物用於製備藥物的用途 - Google Patents

眼用組合物用於製備藥物的用途 Download PDF

Info

Publication number
TWI747816B
TWI747816B TW105106605A TW105106605A TWI747816B TW I747816 B TWI747816 B TW I747816B TW 105106605 A TW105106605 A TW 105106605A TW 105106605 A TW105106605 A TW 105106605A TW I747816 B TWI747816 B TW I747816B
Authority
TW
Taiwan
Prior art keywords
corneal
composition
cornea
dexamethasone
collagen
Prior art date
Application number
TW105106605A
Other languages
English (en)
Chinese (zh)
Other versions
TW201639592A (zh
Inventor
卡洛安 格林
柯林 格林
崔佛 薛爾溫
Original Assignee
紐西蘭商奧克蘭聯合服務有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 紐西蘭商奧克蘭聯合服務有限公司 filed Critical 紐西蘭商奧克蘭聯合服務有限公司
Publication of TW201639592A publication Critical patent/TW201639592A/zh
Application granted granted Critical
Publication of TWI747816B publication Critical patent/TWI747816B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Eyeglasses (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW105106605A 2015-03-05 2016-03-04 眼用組合物用於製備藥物的用途 TWI747816B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ705727 2015-03-05
NZ70572715 2015-03-05

Publications (2)

Publication Number Publication Date
TW201639592A TW201639592A (zh) 2016-11-16
TWI747816B true TWI747816B (zh) 2021-12-01

Family

ID=56848288

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105106605A TWI747816B (zh) 2015-03-05 2016-03-04 眼用組合物用於製備藥物的用途

Country Status (11)

Country Link
US (2) US10842850B2 (enExample)
EP (1) EP3265096B9 (enExample)
JP (4) JP2018513117A (enExample)
KR (1) KR102450674B1 (enExample)
CN (1) CN107530360B (enExample)
AU (1) AU2016226699B2 (enExample)
ES (1) ES2952700T3 (enExample)
MY (1) MY186271A (enExample)
SG (1) SG11201708114SA (enExample)
TW (1) TWI747816B (enExample)
WO (1) WO2016140581A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP4420725A3 (en) 2012-03-29 2025-04-16 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
TWI747816B (zh) * 2015-03-05 2021-12-01 紐西蘭商奧克蘭聯合服務有限公司 眼用組合物用於製備藥物的用途
WO2017015471A1 (en) 2015-07-21 2017-01-26 Avedro, Inc. Systems and methods for treaments of an eye with a photosensitizer
CN110092816B (zh) * 2018-01-29 2023-08-01 上海市第一人民医院 预防和治疗纤维化的小分子多肽及其应用
US20210060017A1 (en) * 2018-02-27 2021-03-04 Shilpa Medicare Ltd Methotrexate ophthalmic solution
CN108728418A (zh) * 2018-06-19 2018-11-02 新乡医学院 一种鸡胚中枢神经系统单个神经元动态研究模型的制备方法及应用
US11672860B2 (en) * 2018-11-02 2023-06-13 Senseonics, Incorporated Drug eluting matrix on analyte indicator
GB201820021D0 (en) * 2018-12-07 2019-01-23 Univ Birmingham Ocular hydrogel compositions
JP2022125941A (ja) * 2021-02-17 2022-08-29 株式会社ティ・エム・ディ コンタクトレンズ
WO2024206871A1 (en) * 2023-03-30 2024-10-03 Cetel Scientific Llc Amniotic and chorionic collagen for ocular surface healing
KR20250092172A (ko) 2022-09-01 2025-06-23 옵티파이 테라퓨틱스 아게 안과용 조성물
US20240119865A1 (en) * 2022-10-07 2024-04-11 Life Model Designs LLC Synthetic blood clot
CN121490062B (zh) * 2026-01-12 2026-05-15 上饶爱尔眼科医院有限公司 含地塞米松的组合物及其在制备治疗视网膜病变的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032131A1 (en) * 1993-09-29 1996-10-17 Alcon Laboratories, Inc. USE OF TGF-β3 TO REDUCE THE FORMATION OF SCAR TISSUE IN RESPONSE TO CORNEAL TRAUMA

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786812A (en) * 1972-03-10 1974-01-22 C Neefe Contact lens for olar drug delivery
US4177268A (en) 1973-05-30 1979-12-04 Jouveinal S.A. Method of alleviating inflammation by administration of dexamethasone derivatives
US5124392A (en) * 1988-10-03 1992-06-23 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
JPH06505965A (ja) * 1990-11-16 1994-07-07 セルトリックス　ファーマシューティカルズ，インコーポレイテッド β型トランスフォーミング成長因子
NZ566132A (en) 2003-02-13 2009-09-25 Anthrogenesis Corp Use of umbilical cord blood to treat inflammation, ParkinsonÆs disease or diabetes
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
US20090232777A1 (en) * 2006-03-01 2009-09-17 Evy Lundgren-Akerlund Expansion and Differentiation of Mesenchymal Stem Cells
GB0604938D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US8110655B2 (en) 2006-11-13 2012-02-07 Auxagen, Inc. Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
EP2229174A1 (en) 2007-12-04 2010-09-22 Novagali Pharma S.A. Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
US7795316B1 (en) 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
CA2716390C (en) 2008-02-25 2016-08-23 Eyegate Pharma S.A.S. Enhanced delivery of a therapeutic to ocular tissues through iontophoresis
EP2962682B1 (en) * 2008-12-11 2018-03-28 Massachusetts Institute Of Technology Method of making a contact lens drug delivery device
US10201548B2 (en) 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
WO2012088044A2 (en) * 2010-12-20 2012-06-28 James Mcmillan Compositions and methods for improving ocular surface health, corneal clarity, optical function and maintaining visual acuity
US20130165419A1 (en) * 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
KR101518370B1 (ko) 2013-06-25 2015-05-07 가톨릭대학교 산학협력단 Il-10 생성 조절 t세포로의 분화 유도용 조성물
CN104548210A (zh) 2014-12-13 2015-04-29 浙江大学 含地塞米松转化生长因子的可控缓释plga微球及制备
TWI747816B (zh) 2015-03-05 2021-12-01 紐西蘭商奧克蘭聯合服務有限公司 眼用組合物用於製備藥物的用途
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032131A1 (en) * 1993-09-29 1996-10-17 Alcon Laboratories, Inc. USE OF TGF-β3 TO REDUCE THE FORMATION OF SCAR TISSUE IN RESPONSE TO CORNEAL TRAUMA

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Carol Greene et al., "Exploring cell plasticity: the corneal keratocyte and beyond", Investigative Ophthalmology & Visual Science, 2013, 54(13)：5250. *
何凱文等, "地塞米松對大鼠角膜酸燒傷療效初探", 國際眼科雜誌, 2014, 14(3)：146-418.
何凱文等, "地塞米松對大鼠角膜酸燒傷療效初探", 國際眼科雜誌, 2014, 14(3)：146-418.; *
郝一豔, "地塞米松在角膜鐵質異物傷術後的應用", 眼外傷職業眼病雜誌, 2010, 32(1)：74-75.
郝一豔, "地塞米松在角膜鐵質異物傷術後的應用", 眼外傷職業眼病雜誌, 2010, 32(1)：74-75.; *

Also Published As

Publication number Publication date
KR102450674B1 (ko) 2022-10-04
EP3265096B9 (en) 2023-10-04
WO2016140581A1 (en) 2016-09-09
EP3265096A4 (en) 2018-10-24
EP3265096B1 (en) 2023-06-07
CN107530360A (zh) 2018-01-02
SG11201708114SA (en) 2017-11-29
JP2023066425A (ja) 2023-05-15
US20180050088A1 (en) 2018-02-22
MY186271A (en) 2021-07-01
JP7641650B2 (ja) 2025-03-07
US20220047676A1 (en) 2022-02-17
AU2016226699A1 (en) 2017-10-26
CN107530360B (zh) 2021-09-17
US10842850B2 (en) 2020-11-24
KR20170132197A (ko) 2017-12-01
JP2018513117A (ja) 2018-05-24
EP3265096A1 (en) 2018-01-10
JP2025032318A (ja) 2025-03-11
JP2021091688A (ja) 2021-06-17
NZ735959A (en) 2021-10-29
EP3265096C0 (en) 2023-06-07
ES2952700T3 (es) 2023-11-03
US11938168B2 (en) 2024-03-26
AU2016226699B2 (en) 2020-10-22
TW201639592A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
JP7641650B2 (ja) 眼科用組成物およびその使用方法
Lin et al. Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction
Liu et al. Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients
JP2022526855A (ja) 間葉系幹細胞由来のセクレトームを作製および使用するためのプロセス
JP2017522016A (ja) 培養哺乳動物輪部幹細胞、その産生方法及びその使用
KR20120102709A (ko) 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
Mertsch et al. The effect of Rho Kinase inhibition on corneal nerve regeneration in vitro and in vivo
JP2023021356A (ja) 網膜疾患を処置するための組成物ならびにそれを作製および使用するための方法
Jirsova The cornea, anatomy and function
CN105555363B (zh) 医药组成物及其用途
You et al. Injectable, antioxidative, and loaded with exosomes/Liproxstatin-1 hydrogel as a potential treatment for retinal ischemia–reperfusion by inhibiting ferroptosis and apoptosis
Zhu et al. Ultrasound targeted microbubble destruction promotes the therapeutic effect of HUMSC transplantation on glaucoma-caused optic nerve injury in rabbits
NZ735959B2 (en) Ophthalmic compositions and methods of use therefor
US20160058796A1 (en) Retina extracellular matrix based biomaterial
US20250222035A1 (en) Processes for making and using a mesenchyme stem cell secretome for limbal stem cell deficiency (lscd) treatment
Shahhossein-Dastjerdi et al. Autophagy and Exocytosis of Lipofuscin Into the Basolateral Extracellular Space of Human Retinal Pigment Epithelium From Fetal Development to Adolescence
Bonzano Cornea to the best of our knowledge
WO2026103774A1 (zh) 一种具有抗血管新生活性的多肽及其应用
WO2025184654A1 (en) Trabecular meshwork cell (tmc) and trabecular meshwork stem cell (tmsc) secretome effects on schlemm's canal endothelial cells (scec)
AU2023338294A1 (en) Preparation and purification methods for mesenchymal stem cell derived secretome
Fronk Methods for Growing Retinal Pigment Epithelial Cells: Current Protocols and Future Recommendations
Chang Analysis of Stem Cells and Wound Healing in the Human Cornea
HK1219691B (en) Pharmaceutical composition and uses thereof